Observations placeholder
Victrelis and Boceprevir
Identifier
024178
Type of Spiritual Experience
Number of hallucinations: 45
Background
A description of the experience
Boceprevir (INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus (HCV) genotype 1. It binds to the HCV nonstructural protein 3 active site.
It was initially developed by Schering-Plough, then by Merck after it acquired Schering in 2009. It was approved by the FDA in May 2011. In January 2015, Merck announced that they would be voluntarily withdrawing Victrelis from the market due to the 'overwhelming superiority of newer direct-acting antiviral agents, such as ledipasvir/sofosbuvir'.
Most common Victrelis side effects from eHealthme
- Fatigue - (1,917 reports)
- Anaemia - (1,609 reports)
- Nausea - (1,392 reports)
- Taste - impaired - (1,014 reports)
- Rashes - (882 reports)
- Weakness - (785 reports)
- Headache - (784 reports)
- Nausea and vomiting - (729 reports)
- White blood cell count decreased - (713 reports)
- Weight decreased - (669 reports)
On Feb, 14, 2017 8,464 people reported to have side effects when taking Victrelis.
Among them, 92 people (1.09%) have Death
On Feb, 14, 2017 8,464 people reported to have side effects when taking Victrelis. Among them, 40 people (0.47%) have Hallucination
On Feb, 14, 2017 8,464 people reported to have side effects when taking Victrelis. Among them, 5 people (0.06%) have Hallucination, Auditory